Cargando…
Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study
BACKGROUND: The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) de...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019640/ https://www.ncbi.nlm.nih.gov/pubmed/35147501 http://dx.doi.org/10.2196/31629 |
_version_ | 1784689334144729088 |
---|---|
author | Majithia, Amit R Erani, David M Kusiak, Coco M Layne, Jennifer E Lee, Amy Armento Colangelo, Francis R Romanelli, Robert J Robertson, Scott Brown, Shayla M Dixon, Ronald F Zisser, Howard |
author_facet | Majithia, Amit R Erani, David M Kusiak, Coco M Layne, Jennifer E Lee, Amy Armento Colangelo, Francis R Romanelli, Robert J Robertson, Scott Brown, Shayla M Dixon, Ronald F Zisser, Howard |
author_sort | Majithia, Amit R |
collection | PubMed |
description | BACKGROUND: The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline glycated hemoglobin (HbA(1c)) ≥8.0% to ≤12.0% experienced a mean HbA(1c) decrease of 1.6% with no significant increase in hypoglycemia. OBJECTIVE: The objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study. METHODS: Study participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed. RESULTS: Of 55 participants, 48 (87%) had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) participants had a net increase in number of diabetes medication classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a glucagon-like peptide-1 receptor agonist increased from 25% (12/48) to 56% (n=27), while the percentages of participants taking a sulfonylurea or dipeptidyl peptidase 4 inhibitor decreased from 56% (n=27) to 33% (n=16) and 17% (n=8) to 6% (n=3), respectively. Prescriptions of other antidiabetic medication classes including insulin did not change significantly. CONCLUSIONS: The Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D. TRIAL REGISTRATION: ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381 |
format | Online Article Text |
id | pubmed-9019640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90196402022-04-21 Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study Majithia, Amit R Erani, David M Kusiak, Coco M Layne, Jennifer E Lee, Amy Armento Colangelo, Francis R Romanelli, Robert J Robertson, Scott Brown, Shayla M Dixon, Ronald F Zisser, Howard JMIR Form Res Original Paper BACKGROUND: The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline glycated hemoglobin (HbA(1c)) ≥8.0% to ≤12.0% experienced a mean HbA(1c) decrease of 1.6% with no significant increase in hypoglycemia. OBJECTIVE: The objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study. METHODS: Study participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed. RESULTS: Of 55 participants, 48 (87%) had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) participants had a net increase in number of diabetes medication classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a glucagon-like peptide-1 receptor agonist increased from 25% (12/48) to 56% (n=27), while the percentages of participants taking a sulfonylurea or dipeptidyl peptidase 4 inhibitor decreased from 56% (n=27) to 33% (n=16) and 17% (n=8) to 6% (n=3), respectively. Prescriptions of other antidiabetic medication classes including insulin did not change significantly. CONCLUSIONS: The Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D. TRIAL REGISTRATION: ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381 JMIR Publications 2022-04-05 /pmc/articles/PMC9019640/ /pubmed/35147501 http://dx.doi.org/10.2196/31629 Text en ©Amit R Majithia, David M Erani, Coco M Kusiak, Jennifer E Layne, Amy Armento Lee, Francis R Colangelo, Robert J Romanelli, Scott Robertson, Shayla M Brown, Ronald F Dixon, Howard Zisser. Originally published in JMIR Formative Research (https://formative.jmir.org), 05.04.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Majithia, Amit R Erani, David M Kusiak, Coco M Layne, Jennifer E Lee, Amy Armento Colangelo, Francis R Romanelli, Robert J Robertson, Scott Brown, Shayla M Dixon, Ronald F Zisser, Howard Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title | Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title_full | Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title_fullStr | Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title_full_unstemmed | Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title_short | Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study |
title_sort | medication optimization among people with type 2 diabetes participating in a continuous glucose monitoring–driven virtual care program: prospective study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019640/ https://www.ncbi.nlm.nih.gov/pubmed/35147501 http://dx.doi.org/10.2196/31629 |
work_keys_str_mv | AT majithiaamitr medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT eranidavidm medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT kusiakcocom medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT laynejennifere medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT leeamyarmento medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT colangelofrancisr medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT romanellirobertj medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT robertsonscott medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT brownshaylam medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT dixonronaldf medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy AT zisserhoward medicationoptimizationamongpeoplewithtype2diabetesparticipatinginacontinuousglucosemonitoringdrivenvirtualcareprogramprospectivestudy |